Kiora Pharmaceuticals KPRX Stock
Kiora Pharmaceuticals Price Chart
Kiora Pharmaceuticals KPRX Financial and Trading Overview
| Kiora Pharmaceuticals stock price | 2.59 USD |
| Previous Close | 2.75 USD |
| Open | 2.65 USD |
| Bid | 1.82 USD x 200 |
| Ask | 3.52 USD x 200 |
| Day's Range | 2.75 - 2.75 USD |
| 52 Week Range | 1.77 - 2.95 USD |
| Volume | 196 USD |
| Avg. Volume | 23.44K USD |
| Market Cap | 12.17M USD |
| Beta (5Y Monthly) | -0.338 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.41 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12 USD |
KPRX Valuation Measures
| Enterprise Value | -4338437 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.2331839 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.78819144 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.446 |
Trading Information
Kiora Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.338 |
| 52-Week Change | -3.20% |
| S&P500 52-Week Change | 18.35% |
| 52 Week High | 2.95 USD |
| 52 Week Low | 1.77 USD |
| 50-Day Moving Average | 2.57 USD |
| 200-Day Moving Average | 2.31 USD |
KPRX Share Statistics
| Avg. Volume (3 month) | 23.44K USD |
| Avg. Daily Volume (10-Days) | 18.29K USD |
| Shares Outstanding | 4.42M |
| Float | 3.85M |
| Short Ratio | 0.2 |
| % Held by Insiders | 3.08% |
| % Held by Institutions | 36.34% |
| Shares Short | 3.86K |
| Short % of Float | 0.090% |
| Short % of Shares Outstanding | 0.090% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:9 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.92% |
| Return on Equity (ttm) | -56.36% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -3875178 USD |
| EBITDA | -9730424 USD |
| Net Income Avi to Common (ttm) | -10986709 USD |
| Diluted EPS (ttm) | -2.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 16.84M USD |
| Total Cash Per Share (mrq) | 3.81 USD |
| Total Debt (mrq) | 333.02K USD |
| Total Debt/Equity (mrq) | 1.98 USD |
| Current Ratio (mrq) | 8.97 |
| Book Value Per Share (mrq) | 3.489 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8506810 USD |
| Levered Free Cash Flow (ttm) | -6363836 USD |
Profile of Kiora Pharmaceuticals
| Country | United States |
| State | CA |
| City | Encinitas |
| Address | 332 Encinitas Boulevard |
| ZIP | 92024 |
| Phone | 858 224 9600 |
| Website | https://www.kiorapharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Q&A For Kiora Pharmaceuticals Stock
What is a current KPRX stock price?
Kiora Pharmaceuticals KPRX stock price today per share is 2.59 USD.
How to purchase Kiora Pharmaceuticals stock?
You can buy KPRX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kiora Pharmaceuticals?
The stock symbol or ticker of Kiora Pharmaceuticals is KPRX.
Which industry does the Kiora Pharmaceuticals company belong to?
The Kiora Pharmaceuticals industry is Biotechnology.
How many shares does Kiora Pharmaceuticals have in circulation?
The max supply of Kiora Pharmaceuticals shares is 4.42M.
What is Kiora Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Kiora Pharmaceuticals PE Ratio is now.
What was Kiora Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Kiora Pharmaceuticals EPS is -2.41 USD over the trailing 12 months.
Which sector does the Kiora Pharmaceuticals company belong to?
The Kiora Pharmaceuticals sector is Healthcare.
Kiora Pharmaceuticals KPRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26151.3 USD — |
+0.66
|
6.6B USD — | 26034.35 USD — | 26225.83 USD — | — - | 6.6B USD — |
|
US Tech Health Care
IXHC
US
|
1378.65 USD — |
+1.27
|
— — | 1366.6 USD — | 1381.83 USD — | — - | — — |
- {{ link.label }} {{link}}
